Mark C. Genovese
Patients with rheumatoid arthritis who previously had an inadequate response to biologic DMARDs demonstrated improved signs and symptoms after receiving daily doses of filgotinib, according to data published in JAMA.
“The study demonstrates that this new selective JAK1 inhibitor works well in patients who have failed standard of care therapies,” Mark C. Genovese, MD, of the Stanford University School of Medicine, told Healio Rheumatology. “The greatest significance to me was the number of patients who could achieve low disease or even remission at 12 and at 24 weeks in this refractory group, including those who had failed three or more biologic agents.”
To analyze the impact filgotinib (Galapagos NV) has – compared with placebo – on the signs and symptoms of RA among patients who experienced little or no relief from biologic DMARDs, Genovese and colleagues conducted the phase 3 FINCH 2 study, a 24-week, randomized trial of 449 adults in 114 centers, across 15 countries in North America and Europe. All participants were aged 18 years or older, with moderate-to-severe active RA and a previous inadequate response or an intolerance to one or more biological DMARD.
Patients with RA who previously had an inadequate response to biologic DMARDs demonstrated improved signs and symptoms after receiving filgotinib, according to data.
Participants were randomly assigned to receive either 100 mg or 200 mg of filgotinib, or placebo, once daily. Patients also continued stable treatment with conventional synthetic DMARDs. The primary outcome was the proportion of participants achieving ACR20 criteria at week 12. Secondary endpoints included low disease activity, change in health assessment questionnaire-disability index, 36-item short-form health survey physical component and functional assessment of chronic illness therapy-fatigue scores at week 12. Genovese and colleagues also assessed 12-week remission and adverse events.
According to the researchers, 381 participants completed the study. At week 12, 66% of patients treated with 200 mg of filgotinib, as well as 57.5% of those in the 100-mg group, demonstrated ACR20 response, compared with 31.1% of those who received placebo (P < .001). This included patients with prior, inadequate treatments with three or more biologic DMARDs — 70.3% in the 200-mg group, 58.8% in the 100-mg group and 17.6% among those who received placebo (P < .001).
The most common adverse events included nasopharyngitis, reported in 10.2% of patients in the 200-mg group, as well as headache, nasopharyngitis and upper respiratory infection, with each experienced by 5.9% of patients in the 100-mg group. In addition, there were four uncomplicated cases of herpes zoster and one retinal vein occlusion among patients treated with filgotinib. There were no opportunistic infections, active tuberculosis, malignancies, gastrointestinal perforations or deaths.
“This is continuing to evolve based on the results of the phase 3 program and the integrated safety across all studies done to date,” Genovese said. “I’m hoping that regulators and insurers can make this data available for as broad a population as possible. This report should provide optimism and hope for those patients who are getting inadequate responses from their current therapy.”
In a related editorial, Jasvinder A. Singh, MBBS, MPH, of the University of Alabama at Birmingham, called the study and the resulting data “pivotal” for patients with RA who are nonresponsive or intolerant to current treatments. However, he added that the price of oral JAK inhibitors will have to be reduced to help promote their use.
“Patients and clinicians express frustration over the high pricing of new RA therapies because a portion of the cost is often passed on to the patients by the health insurance plan, which limits access to these therapies,” Singh wrote in JAMA. “Head-to-head comparison of filgotinib with other JAK inhibitors, biologic DMARDs, and triple conventional DMARD therapy will further define the most appropriate use of filgotinib for patients with RA by examining the comparative efficacy and safety.” – by Jason Laday
Disclosure : Genovese reports grants and personal fees from AbbVie, Astellas, Eli Lilly, EMD Serono, Genentech/Roche, Gilead, Pfizer, Sanofi and Vertex, as well as grants from Galapagos. Please see the full study for additional authors’ disclosures. Singh reports personal fees from the ACR, ClearView Healthcare Partners, Clinical Care Options, Fidia, Horizon, Medisys, Medscape, the NIH, Putnam Associates, Spherix, UBM LLC and WebMD; owning stock options in Amarin Pharmaceuticals and Viking Therapeutics; and serving on the OMERACT executive board, the FDA advisory committee and the Veterans Affairs Rheumatology Field Advisory Committee.